Browsing by Author "Melek, Engin"

Now showing 1 - 6 of 6

Early Diabetic Nephropathy and Endothelial Dysfunction in Children with Type 1 Diabetes Mellitus
(2015) Aynaci, Sercan; Bayazit, Aysun K.; Melek, Engin; Gurbuz, Fatih; Atmis, Bahriye; Anarat, Ruksan; Yuksel, Bilgin; Anarat, Ali
Education Status of Pediatric Dialysis Patients in Turkey
(2018) Delibas, Ali; Ekim, Mesiha; Yildirim, Zeynep Yuruk; Dusunsel, Ruhan; Kara, Ashhan; Noyan, Aytul; Bayazit, Aysun Karabay; Conkar, Secil; Yazicioglu, Burcu Ozer; Serdaroglu, Erkin; Aksoy, Gulsah Kaya; Akinci, Nurver; Yilmaz, Dilek; Bek, Kenan; Ertan, Pelin; Gurgoze, Metin Kaya; Kabasakal, Caner; Doven, Serra Surmeli; Turkkan, Ozde Nisa; Gunay, Neslihan; Parmaksiz, Gonul; Melek, Engin; Erdogan, Semra; Ezgu, Sevcan Azime Bakkaloglu; Sever, Lale; https://orcid.org/0000-0003-2373-1837; AAD-5713-2021; AAM-2935-2021
Extra-Renal Manifestations of Atypical Hemolytic Uremic Syndrome in Children
(2018) Fidan, Kibriya; Goknar, Nilufer; Gulhan, Bora; Melek, Engin; Yildirim, Zeynep Y.; Baskin, Esra; Hayran, Mutlu; Gulleroglu, Kaan; Ozcakar, Zeynep B.; Ozaltin, Fatih; Soylemezoglu, Oguz; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0003-1434-3824; 29610995; B-5785-2018; AAJ-8833-2021
Atypical hemolytic uremic syndrome (aHUS) is a chronic disease characterized by thrombotic microangiopathy and a high risk of end-stage kidney disease. Dysregulation and/or excessive activation of the complement system results in thrombotic microangiopathy. Interest in extrarenal manifestations of aHUS is increasing. This study aimed to determine the clinical characteristics of patients with extrarenal manifestations of aHUS in childhood. This study included 70 children with extrarenal manifestations of HUS from the national Turkish aHUS Registry. The demographics, clinical characteristics, genetic test results, all treatments, and renal/hematologic status of aHUS patients with extrarenal involvement were recorded. The most common extrarenal manifestation was neurological system involvement (n = 46 [27.2%]), followed by gastrointestinal (n = 20 [11.8%]), cardiovascular (n = 12 [7%]), and respiratory (n = 12 [7%]) involvement. The patients with neurological involvement had a higher mortality rate and a lower estimated glomerular filtration rate (eGFR) than the other patients at last follow-up. Eculizumab (with or without plasma exchange/plasma infusion) treatment increased the renal and hematologic recovery rates. The most common and serious extrarenal manifestation of aHUS is neurological involvement and treatment outcome findings presented herein are important to all relevant clinicians.
Predictive Value of Early Period Doppler Ultrasonography on Early and Long-Term Allograft Function
(2016) Melek, Engin; Baskin, Esra; Gulleroglu, Kaan; Uslu, Nihal; Moray, Gokhan; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-6733-8669; https://orcid.org/0000-0003-2498-7287; B-5785-2018; AAJ-8833-2021; ABC-5258-2020; AAE-1041-2021
Timing for Removal of Peritoneal Dialysis Catheters in Pediatric Renal Transplant Patients
(2016) Melek, Engin; Baskin, Esra; Gulleroglu, Kaan Savas; Kirnap, Mahir; Moray, Gokhan; Haberal, Mehmet; 0000-0003-4361-8508; 0000-0003-1434-3824; 0000-0003-2498-7287; 0000-0002-3462-7632; 27805518; B-5785-2018; AAJ-8833-2021; AAH-9198-2019; AAE-1041-2021; AAJ-8097-2021
Objectives: Peritoneal dialysis, the preferred long-term renal replacement modality in the pediatric population, can also be used during the post transplant period. Although it is well known that peritonitis or other complications may occur related to the peritoneal dialysis catheter, less is known about complications related to the peritoneal dialysis during the post transplant period. Our objective was to evaluate the complications related to use of a peritoneal dialysis catheter during the posttransplant period and to determine the optimum time for removal of the peritoneal dialysis catheter. Material and Methods: We retrospectively analyzed 33 chronic peritoneal dialysis patients. Pretransplant and posttransplant demographics and clinical and laboratory data for each patient were recorded, including incidence of peritonitis and incidence of peritoneal dialysis catheter requirement after transplant. Results: Mean age of patients at transplant was 12.8 +/- 4.0 years (range, 3.5-18.0 y). Mean catheter removal time was 81.1 +/- 36.2 days (range, 22.0-152.0 d). The peritoneal dialysis catheter was used in 6 of 33 patients (18.2%); none of these patients developed peritonitis. In contrast, 2 of the 27 patients who did not use the peritoneal dialysis catheter developed peritonitis. Our data suggest that the need for catheter use occurs predominantly during the first month, and infectious complications usually happen later. Conclusions: Previously, the trend was to not remove the peritoneal dialysis catheter at the time of transplant. However, in light of recent literature and our present study, we recommend that the time of catheter removal should be modified and decided for each patient on an individual basis.
Turkish Atypical Hemolytic Uremic Syndrome Registry: Eculizumab Treatment İn Ahus Patients
(2018) Baskin, Esra; Canpolat, Nur; Gulleroglu, Kaan; Yilmaz, Alev; Melek, Engin; Yuksel, Selcuk; Gulhan, Bora; Kalyoncu, Mukaddes; Parmaksiz, Gonul; Ozcakar, Birsin; Ozaltin, Fatih; Soylemezoglu, Oguz; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0003-2373-1837; B-5785-2018; F-3294-2013; AAM-2935-2021